Lapierre Y D, Oyewumi K L
Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(4-6):805-7. doi: 10.1016/0278-5846(83)90071-4.
Suriclone, a new psychotherapeutic agent chemically unrelated to benzodiazepines or phenothiazines was assessed in a single-blind dose-ranging study to determine its efficacy and safety in out-patients with generalized anxiety disorder. Suriclone was an effective anxiolytic drug at a dose range between 1.2 mg. and 3.6 mg. per day. The drug, when effective, has a duration of action between 6 and 8 hours. There was no evidence of a rebound phenomenon. There was, however, a rapid return to pre-treatment level of anxiety. Side effects were few, mild and transient. This new molecule may herald an advance in the treatment of these disorders and should be investigated more fully.
舒立克隆是一种化学结构与苯二氮䓬类或吩噻嗪类无关的新型心理治疗药物，在一项单盲剂量范围研究中对其在广泛性焦虑症门诊患者中的疗效和安全性进行了评估。舒立克隆在每天1.2毫克至3.6毫克的剂量范围内是一种有效的抗焦虑药物。该药物起效时，作用持续时间为6至8小时。没有证据表明存在反跳现象。然而，焦虑水平会迅速恢复到治疗前的水平。副作用很少，轻微且短暂。这种新分子可能预示着这些疾病治疗方面的进展，应该进行更全面的研究。
